CarePartners of Connecticut

Hepatitis C Medication Request Form

Today's date ___/___/___

Submit form to:

Fax: 617.673.0956

Mail: CarePartners of Connecticut
705 Mount Auburn Street
Watertown, MA 02472
Attn: Pharmacy Utilization Management Department

Member Information

Last Name:	First Name:
Member ID#:	Member DOB:

Prescriber Information

Prescribing Clinician:	Phone #:
Specialty (required):	Secure Fax #:
NPI #:	DEA/xDEA:
Prescriber Point of Contact Name (POC) (if different than provider):	
POC Phone #:	POC Secure Fax #:

Medication Information

Requested drug(s):

☐ Harvoni ☐ Viekira Pak ☐ Viekira XR ☐ Epclusa ☐ Sovaldi ☐ Technivie ☐ Vosevi ☐ Mavyret

☐ Zepatier ☐ Daklinza ☐ Ribavirin (generic) ☐ Ribavirin (Brand) ☐ Other: ______________________________

Dose(s): ____ Requested Duration of Treatment: ________________weeks

Type of therapy: ☐ Initial ☐ Continuation - weeks remaining: _________ Anticipated Start Date: _________________

Clinical Information

Diagnosis:

☐ B18.2 Hepatitis C (chronic)

HCV Genotype: ☐1a ☐1b ☐2 ☐3 ☐4 ☐5 ☐6

Stage of Hepatic Fibrosis: ☐F0 ☐F1 ☐F2 ☐F3 ☐F4

For members with early stage liver disease (Metavir Score F0-F2), please describe the medical necessity for requesting treatment at this time:
____
____
____

Is the medication prescribed by a gastroenterologist, infectious disease specialist, or hepatologist?	☐ Yes	☐ No
Was the staging of hepatic fibrosis performed by a specialist through one of the following?	☐ Yes	☐ No

Please check all that apply and attach documentation including medical records and results of diagnostic tests: ☐ Liver biopsy confirming METAVIR score ☐ Transient elastography (Fibroscan) score ☐ Fibrotest (FibroSURE) score of greater ☐ Radiological imaging ☐ APRI score ☐ Physical findings or clinical evidence consistent with cirrhosis as attested by the prescriber		
Is there documented evidence of chronic liver disease, or in the absence of chronic liver disease, serologic evidence of persistent infection for at least six months?	☐ Yes	☐ No
Does the patient have HIV coinfection?	☐ Yes	☐ No
Has Hepatitis B screening been performed?	☐ Yes	☐ No
If patient has active Hepatitis B infection, has the risk of Hepatitis B reactivation been assessed? ***Caution:*** *FDA has warned about the risk of Hepatitis B reactivating in some patient treated with direct acting antiviral agents for Hepatitis C. AASLD recommends treating Hepatitis B concurrently or prior to Hepatitis C treatment.*	☐ Yes	☐ No
Does the patient have severe renal impairment or end-stage renal disease, or require dialysis? Confirm the patient's GFR range: ☐ 0 – 14 ☐ 15 – 29 ☐ > / = 30	☐ Yes	☐ No
Has the patient been previously treated for Hepatitis C and failed treatment? *If yes, when?* _______________ *What treatment(s)?* ____________________________________ Response to treatment: ☐ Relapsed ☐ Partial response ☐ Did not complete ☐ Null response (<2 log reduction in HCV RNA at week 12) Adverse reaction? ☐ Yes ☐ No	☐ Yes	☐ No
HCV RNA levels: Baseline within 6 months of beginning treatment (required): ___________ IU/mL Date of lab work: _______________ **Post-therapy:** 12 weeks after completion of treatment: ___________________ IU/mL Date of lab work: _______________________		

Has there been confirmation that the patient does not have a genotype 1a with NS3 Q80K polymorphism? (Olysio only)	☐ Unknown	☐ Yes	☐ No
Has there been confirmation that the patient does not have a genotype 1a with a baseline NS5A polymorphism? (Zepatier only)	☐ Unknown	☐ Yes	☐ No
Will hepatic laboratory testing be performed prior to therapy, at treatment week 8, and as clinically indicated?		☐ Yes	☐ No
Does the patient have a diagnosis of hepatocellular carcinoma that meets Milan criteria?		☐ Yes	☐ No
If the patient requires a dosage form other than ribavirin 200mg capsules or tablets, document clinical reason and provide dosage form. *Dosage form:* ____ *Clinical reason*: ____			
Are any of the following statements true? ☐ Patient is pregnant or is planning to become pregnant within 6 months after completion of treatment			

☐ Patient is male with a female partner who is pregnant or is planning to become pregnant within 6 months after completion of treatment ☐ None of the above		
Is the member currently awaiting a liver transplant?	☐ Yes	☐ No
Does the member have cirrhosis? *If yes, please choose one:* ☐ Compensated (Child-Turcotte-Pugh Class A; no major complication of cirrhosis) ☐ Decompensated (Child-Turcotte-Pugh Class B or C)	☐ Yes	☐ No
Is the patient being managed in a liver transplant center?	☐ Yes	☐ No
Is the member actively participating in illicit substance abuse or alcohol abuse?	☐ Yes	☐ No
Is there documented attestation that the member has been assessed for potential nonadherence?	☐ Yes	☐ No
Is the member is receiving substance or alcohol abuse counseling services or seeing an addiction specialist as an adjunct to HCV treatment?	☐ Yes	☐ No
Has a treatment plan been developed and discussed with the patient?	☐ Yes	☐ No
Did the prescriber identify any potential issues with adherence? *If yes, please describe:* ____	☐ Yes	☐ No
Have drug interactions been reviewed and evaluated?	☐ Yes	☐ No

Does this member reside in long-term care? ☐ Yes ☐ No

Is the member enrolled in Hospice? ☐ Yes ☐ No If no, disenrollment date: ________________________________

Is the drug related to the terminal illness or related conditions? ☐ Yes ☐ No

Provide an explanation of why the drug being prescribed is unrelated to the terminal illness/related conditions:

____

____

Is this a request for a formulary tier exception (the member's drug plan charges a higher copayment for the drug prescribed than it charges for another drug that treats the condition, and I want to pay the lower copayment – excludes nonformulary drugs and drugs on the specialty tier)? ☐ Yes* ☐ No

*If yes, a supporting statement from the prescribing physician is required. Please specify the request: (1) formulary or preferred drugs contraindicated or tried and failed, or tried and not as effective as requested drug; (2) if therapeutic failure, length of therapy on each drug and adverse outcome; (3) if not as effective, length of therapy on each drug and outcome

By checking the following box, I certify that applying the standard review time frame may seriously jeopardize my patient's life, health, or ability to attain, maintain, or regain maximum function. ☐ Request for expedited review

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

____

Prescriber signature (STAMP NOT ACCEPTED) Date